INTRODUCTION {#s1}
============

The incidence of hepatocellular carcinoma (HCC) has dramatically increased in Western countries and has become more prevalent in Asian countries \[[@R1], [@R2]\]. Although significant improvement in diagnosis and treatment of HCC has been achieved, the outcome of patients remains dismal with a median survival of merely a few months \[[@R3]\]. This poor prognosis is due to high recurrent and metastatic rates even after the use of current treatment modalities \[[@R3]\]. Furthermore, biomarkers that are currently used clinically to predict the prognosis of HCC patients after curative surgical resection remain unsatisfactory in terms of both accuracy and reproducibility. Therefore, it remains clinically important to identify novel prognostic biomarkers to improve the diagnosis and treatment of HCC patients.

Jumonji AT-rich interactive domain 1B (JARID1B) is a member of the family of JmjC domain-containing proteins that specifically removes methyl residues from tri-, di-, and monomethylated lysine 4 on histone H3 lysine 4 (H3K4) that are associated with active genes \[[@R4], [@R5]\]. JARID1B is a transcriptional repressor that harbors intrinsic histone demethylase activity. Trimethylation at H3K4 is an important histone mark associated with actively transcribed genes, and JARID1B specifically demethylates H3K4me3 to a transcriptionally inactive state \[[@R6]\]. JARID1B is up-regulated in multiple tumor cell lines \[[@R4], [@R7]-[@R11]\]. Furthermore, JARID1B promotes proliferation of cancer cells, and knockdown of JARID1B causes a significant delay in the G1/S transition \[[@R12], [@R13]\]. JARID1B appears to promote breast tumorigenesis through the specific repression of antiproliferative genes including the BRCA1 breast tumor suppressor gene \[[@R8]\]. Thus, JARID1B may act as an oncogene, but whether JARID1B plays a role in HCC formation and metastasis remains unknown.

The vast majority of HCC patients succumb to their disease as a result of metastasis \[[@R14]\]. Currently, treatment options for metastatic HCC are limited and ineffective. Therefore, tremendous effort has been focused on the understanding of the mechanisms by which metastasis occurs in order to provide a more rational approach in the development of future metastatic hepatocellular carcinoma treatments. However, how metastases are formed remains less understood. Mounting evidence shows that in epithelial cancers, including HCC, induction of epithelial-mesenchymal transition (EMT) is a major event that provides mobility to cancer cells in order to generate metastases \[[@R15], [@R16]\]. EMT is characterized by the loss of epithelial characteristics and acquisition of a mesenchymal phenotype, which confers the ability for cancer cells to invade adjacent tissue and migrate to distant sites, where these cancer cells proliferate to generate new tumors \[[@R17]\]. Hence, clarifying the regulation of proliferation and EMT will greatly benefit our understanding of HCC metastasis.

In the current study, we show that JARID1B overexpression predicts poor prognosis in HCC patients undergoing curative resection. Additionally, we present the evidence that JARID1B expression promotes HCC cells growth, invasion, metastasis and EMT. These functional effects of JARID1B were exerted through control of PTEN transcriptional expression via H3K4me3. The down-regulation of PTEN and upregulation of the PI3K pathway triggered by JARID1B therefore enforce HCC cells oncogenesis and metastasis. Our findings provide a novel mechanistic role of JARID1B in HCC metastasis, suggesting that JARID1B may serve as a potential therapeutic target for advanced HCCs.

RESULTS {#s2}
=======

JARID1B is highly expressed and correlated with distant metastasis in HCC {#s2_1}
-------------------------------------------------------------------------

To investigate whether JARID1B might be involved in HCC, the mRNA expression level of JARID1B in HCC tissues and its matched normal adjacent tissues was determined by qRT-PCR in 38 samples. As compared with normal tissues, HCC specimens showed overexpression of JARID1B (Figure [1A](#F1){ref-type="fig"}). We then analyzed JARID1B expression in HCCs without or with distant metastasis; we found that JARID1B mRNA overexpression was significantly correlated with distant metastasis in HCC tissues (Figure. [1C](#F1){ref-type="fig"}). The protein level of JARID1B in these tissue samples were also analyzed by western blot (Figure [1B](#F1){ref-type="fig"}). The protein level of JARID1B was upregulated in HCCs samples as compared with the normal adjacent tissues samples. Furthermore, we found that JARID1B protein expression was also significantly correlated with distant metastasis in HCC tissues (Figure. [1D](#F1){ref-type="fig"}). As showed in [Supplemental Figure 1A and 1B](#SD1){ref-type="supplementary-material"}, expression level of JARID1B protein and mRNA in mesenchymal HCC cell lines was higher than that in the epithelia HCC cell lines. These data demonstrated that the upregulation of JARID1B might be relevant to development of HCC.

![JARID1B is highly expressed in HCC\
**A**, JARID1B mRNA expression was analyzed by quantitative RT-PCR in tumors and adjacent tissues. **B**, JARID1B protein expression was analyzed by Western blot in tumors and adjacent tissues and the representative results were shown. **C**, comparison of the expression levels of JARID1B mRNA in adjacent tissues, not metastasis and metastatic HCCs. **D**, comparison of the relative expression levels of JARID1B protein in adjacent tissues, not metastasis and metastatic HCCs. ^\*\*^, compared with adjacent tissues *P* \< 0.01; ^\#\#^, compared with not metastasis tissues *P* \< 0.01; Error bars, SD.](oncotarget-06-12723-g001){#F1}

We examined JARID1B protein expression in more HCC samples by IHC (Figure [2A](#F2){ref-type="fig"}). We observed that the level of JARID1B positive cells was markedly higher in HCC tissues than the level in the normal liver tissues (Figure [2B](#F2){ref-type="fig"}). Most importantly, JARID1B overexpression was consistently significantly correlated to distant metastasis in these HCC samples (Figure [2B](#F2){ref-type="fig"}). To investigate the relationship between JARID1B expression and clinicopathological parameters in the 178 cases with HCCs, these cases were first divided into two subgroups: "low JARID1B expression" and "high JARID1B expression" as defined in the immunohistochemistry section of "Materials and methods". Significant correlations were found between JARID1B expression and tumor diameter, microvascular invasion, and tumor differentiation. There were no statistical connections between JARID1B expression and the rest clinicopathological parameters, such as patient age, gender, and HBsAg (Table [1](#T1){ref-type="table"}). The association between JARID1B expression in HCC and the survival time of selected patients was analyzed with Kaplan-Meier survival analysis (Figure [2C](#F2){ref-type="fig"}). The median overall survival time of high JARID1B expression group was significantly shorter than that of low JARID1B expression group (*P* \< 0.001). These results collectively indicate a functional role of JARID1B in aggressive behaviors of HCCs.

![JARID1B is correlated with distant metastasis in HCC\
**A**, JARID1B protein expression was analyzed by immunohistochemical analysis in 178 cases HCC tissues and the representative results were shown. **B**, semiquantification of JARID1B expression in normal tissues, primary HCC tissues without or with distant metastasis. Normal, normal liver tissues; no distant met, primary cancers without distant metastasis (in situ); distant met, primary cancers with distant metastasis. \*\*, *P* \< 0.01 is based on the Student *t* test. Error bars, SD. **C**, the association between JARID1B expression in HCC and the survival time of selected patients was analyzed with Kaplan-Meier survival analysis. Scale bars, 50 μm (upper) and 20 μm (lower) in A.](oncotarget-06-12723-g002){#F2}

###### JARID1B staining and clinicopathologic characteristics of 178 hepatocellular carcinoma patients

  Variables                    JARID1B staining   Total      Pa    
  ---------------------------- ------------------ ---------- ----- ----------
  **Age (y)**                                                      
   ≤50                         53 (74%)           19 (26%)   72    0.084
   \>50                        73 (69%)           33 (31%)   106   
  **Sex**                                                          
   Male                        119 (79%)          32 (21%)   151   0.399
   Female                      22 (81%)           5 (19%)    27    
  **HBsAg**                                                        
   Negative                    39 (83%)           8 (17%)    47    0.094
   Positive                    94 (72%)           37 (28%)   131   
  **HCV**                                                          
   Negative                    127 (74%)          45 (26%)   172   0.257
   Positive                    5 (83%)            1 (17%)    6     
  **AFP**                                                          
   ≤20                         62 (78%)           17 (22%)   79    0.318
   \>20                        71 (72%)           28 (28%)   99    
  **γ-GT(U/L)**                                                    
   ≤54                         63 (73%)           21 (27%)   86    0.336
   \>54                        73 (79%)           19 (21%)   92    
  **Liver cirrhosis**                                              
   No                          24 (77%)           7 (23%)    31    0.362
   Yes                         109 (74%)          38 (26%)   147   
  **Tumor diameter (cm)**                                          
   ≤5                          101 (82%)          22 (18%)   123   0.026
   \>5                         39 (71%)           16 (29%)   55    
  **Microvascular invasion**                                       
   Absence                     62 (83%)           13 (17%)   75    \< 0.001
   Present                     58 (56%)           51 (44%)   103   
  **Tumor encapsulation**                                          
   Complete                    65 (75%)           22 (25%)   87    0.268
   None                        64 (71%)           26 (29%)   90    
  **Tumor differentiation**                                        
   I+II                        99 (78%)           28 (22%)   127   0.001
   III+IV                      31 (61%)           20 (39%)   51    
  **TNM stage**                                                    
   I                           115 (75%)          38 (25%)   153   0.446
   II + III                    19 (76%)           6 (24%)    25    

**Abbreviations:** HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; γ-GT, γ-glutamyl transferase; TNM, tumor-nodesmetastasis.

*p*-value \< 0.05 was considered statistically significant. *p*-values were calculated using the Pearson chi-square test.

JARID1B promotes proliferative capacity of HCC cells {#s2_2}
----------------------------------------------------

In order to test the oncogenic activity of JARID1B in HCC, we retrovirally established stable overexpression of JARID1B in Huh7 and HepG2 cells, and silencing of JARID1B in SNU423 and SK-Hep1 cells. The levels of JARID1B in these resultant cell lines were verified by western blotting (Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}) and qRT-PCR ([Supplemental Figure 2A and 2B](#SD1){ref-type="supplementary-material"}). Compared to vector-only controls, both Huh7-pBabe-JARID1B and HepG2-pBabe-JARID1B cells had significant increases in cell proliferation by MTT assay (Figure [3C](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}) and generated more numbers and larger colonies (Figure [3G](#F3){ref-type="fig"} and [3H](#F3){ref-type="fig"}). In contrast, silencing of JARID1B in SNU423 and SK-Hep1 cells significantly reduced cell proliferation (Figure [3E](#F3){ref-type="fig"} and [3F](#F3){ref-type="fig"}) and clonogenicity (Figure [3I](#F3){ref-type="fig"} and [3J](#F3){ref-type="fig"}). Consistent with these observations and previous reports \[[@R8], [@R23]\], we confirmed that cyclin D1, which promotes G(1) progression, was modulated upon JARID1B expression, JARID1B overexpression significantly increased the expression of Cyclin D1 while silencing JARID1B dramatically decreased its expression level (Figure [3K](#F3){ref-type="fig"} and [3L](#F3){ref-type="fig"}, [Supplemental Figure 2C and 2D](#SD1){ref-type="supplementary-material"}). To further understand and characterize the role of JARID1B in control of HCC cell growth, we analyzed the apoptotic activity of JARID1B in HCC cells. Annexin V binding assay showed that ectopic JARID1B expression reduced the cell proportion in apoptosis ([Supplemental Figure 3A and 3B](#SD1){ref-type="supplementary-material"}) and silencing JARID1B expression drastically increased the population of apoptotic cells ([Supplemental Figure 3C and 3D](#SD1){ref-type="supplementary-material"}). Taking together, these results suggest that JARID1B is an important regulator of proliferation in HCC cells.

![JARID1B promotes proliferative capacity of HCC cells\
**A** and **B**, expression level of JARID1B was measured by Western blotting. **C**-**F**, Cell proliferation was examined by MTT assays. **G**-**J**, cell proliferation was examined by colony formation assays. **K** and **L**, expression level of Cyclin D1 was measured by Western blotting. For colony formation assay, colonies containing more than 50 cells were counted and plotted; representative plates are shown in insets. \*\*, *P* \< 0.01 is based on the Student *t* test. All results are from three independent experiments. Error bars, SD.](oncotarget-06-12723-g003){#F3}

JARID1B regulates the transition between epithelial and mesenchymal phenotypes in HCC cells {#s2_3}
-------------------------------------------------------------------------------------------

To investigate whether JARID1B positively regulates cell migration and invasion, we first observed the morphological changes and found that both Huh7-pBabe-JARID1B and HepG2-pBabe-JARID1B cells exhibited fibroblastic morphology (Figure [4A](#F4){ref-type="fig"}). This observation was further confirmed by expression analyses of epithelial and mesenchymal markers. We showed that JARID1B overexpression decreased the levels of epithelial markers (E-cadherin and α-catenin) and increased the levels of mesenchymal markers (N-cadherin and vimentin) in both cell lines (Figure [4B](#F4){ref-type="fig"} and [4C](#F4){ref-type="fig"}). Conversely, both SNU423-pSuper-shJARID1B and SK-Hep1-pSuper-shJARID1B cells reverted to an epithelial phenotype as compared to their respective control cells (Figure [4D](#F4){ref-type="fig"}). Consistent with this, silencing JARID1B increased levels of epithelial markers, and decreased levels of mesenchymal markers (Figure [4E](#F4){ref-type="fig"} and [4F](#F4){ref-type="fig"}). Taken together, these findings suggest that JARID1B plays an important role in regulating EMT-MET plasticity of HCC cells.

![JARID1B regulates the transition between epithelial and mesenchymal phenotypes in HCC cells\
**A**, representative phase-contrast images of Huh-7 and HepG2 cells showed JARID1B overexpression-modulated morphologic changes. **B**, expression of epithelial and mesenchymal marker was analyzed by immunofluorescence stains in Huh-7 and HepG2 cells. **C**, expression of epithelial and mesenchymal marker was analyzed by Western blotting in Huh-7 and HepG2 cells. **D**, representative phase-contrast images of SNU423 and SK-Hep1 cells showed JARID1B knockdown-modulated morphologic changes. E, expression of epithelial and mesenchymal marker was analyzed by immunofluorescence stains in SNU423 and SK-Hep1 cells. F, expression of epithelial and mesenchymal marker was analyzed by Western blotting in SNU423 and SK-Hep1 cells.](oncotarget-06-12723-g004){#F4}

JARID1B promotes migratory and invasive capacities of HCC cells *in vitro* {#s2_4}
--------------------------------------------------------------------------

The effect of JARID1B on cell migration was first assessed by wound healing assay. Both Huh7-pBabe-JARID1B and HepG2-pBabe-JARID1B cells had significantly faster closure of the wound area compared to their control cells (Figure [5A and 5B](#F5){ref-type="fig"}). This result was confirmed by Boyden\'s chamber assay (Figure [5C and 5D](#F5){ref-type="fig"}). Moreover, Huh7-pBabe-JARID1B and HepG2-pBabe-JARID1B cells showed a greater degree of invasion through Matrigel (Figure [5C and 5D](#F5){ref-type="fig"}). In contrast, silencing JARID1B dramatically reduced the migratory and invasive capacity of SNU423 and SK-Hep1 cells (Figure [5E - H](#F5){ref-type="fig"}), suggesting that restoration of an epithelial phenotype through MET may dampen or inhibit their mobility potential. These results indicate that JARID1B promotes migratory and invasive behaviors in HCC cells.

![JARID1B promotes migratory and invasive capacities of HCC cells *in vitro*\
Huh7-pBabe-JARID1B (**A**), HepG2-pBabe-JARID1B (**B**) and theirs control vector cells were subjected to wound healing assays; the uncovered areas in the wound healing assays were quantified as a percentage of the original wound area. Huh7-pBabe-JARID1B (**C**), HepG2-pBabe-JARID1B (**D**) and theirs control vector cells were subjected to Transwell migration (C and D, top), and Matrigel invasion assays (C and D, bottom), quantification of migrated cells through the membrane and invaded cells through Matrigel of each cell line are shown as proportions of their vector controls. SNU423-pSuper-shJARID1B (**E**), SK-Hep1-pSuper-shJARID1B (**F**) and theirs control vector cells were subjected to wound healing assays, the uncovered areas in the wound healing assays were quantified as a percentage of the original wound area. SNU423-pSuper-shJARID1B (**G**), SK-Hep1-pSuper-shJARID1B (**H**) and theirs control vector cells were subjected to Transwell migration (G and H, top), and Matrigel invasion assays (G and H, bottom), quantification of migrated cells through the membrane and invaded cells through Matrigel of each cell line are shown as proportions of their vector controls. \*\*, *P* \< 0.01 is based on the Student *t* test. All results are from three independent experiments. Error bars, SD.](oncotarget-06-12723-g005){#F5}

JARID1B promotes tumorigenesis and metastasis *in vivo* {#s2_5}
-------------------------------------------------------

To extend our *in vitro* observations, we investigated whether JARID1B could regulate tumorigenic and metastatic capacity of HCC cells in vivo. HepG2-pBabe-JARID1B, SK-Hep1-pSuper-shJARID1B and their corresponding control cells were subcutaneously injected into nude mice. Tumor size was measured every week up to 6 weeks. As expected, the tumors from HepG2-pBabe-JARID1B cells grew more rapidly at the implantation site than the control cells (Figure [6A - C](#F6){ref-type="fig"}). In contrast, silencing JARID1B in the typically aggressive SK-Hep1 cells led to a dramatic decrease in tumor volume and weight (Figure [6D - F](#F6){ref-type="fig"}).

![JARID1B promotes tumorigenesis and metastasis *in vivo*\
**A** and **D**, representative images of HepG2-pBabe-JARID1B (A), SK-Hep1-pSuper-shJARID1B (D) or their control cell tumors by subcutaneous injection. **B** and **E**, growth curve of tumors formed by HepG2-pBabe-JARID1B (B), SK-Hep1-pSuper-shJARID1B (E) or their control cells by subcutaneous injection. **C** and **F**, the weight of tumors formed by HepG2-pBabe-JARID1B (C), SK-Hep1-pSuper-shJARID1B (F) or their control cells at harvest time. **G**, the total numbers of mice with distant metastasis at 60 days after injection of HepG2-pBabe-JARID1B, SK-Hep1-pSuper-shJARID1B or their control cells. **H** and **I**, the numbers of metastatic foci per section in lung of individual mouse with injection of HepG2-pBabe-JARID1B (H), SK-Hep1-pSuper-shJARID1B (I) or their control cells. n=5 for subcutaneous transplantation and n=5 for tail vein injection. \*\*, *P* \< 0.01 is based on the Student *t* test. All results are from three independent experiments. Error bars, SD.](oncotarget-06-12723-g006){#F6}

We then investigated the functional relevance of JARID1B for metastasis *in vivo*. HepG2-pBabe-JARID1B, SK-Hep1-pSuper-shJARID1B and their corresponding control cells were injected into nude mice through the tail vein. JARID1B overexpression not only significantly increased the number of mice with distant metastasis (Figure [6G](#F6){ref-type="fig"}), but also dramatically increased the number of metastatic tumors in lung of each mouse (Figure [6H](#F6){ref-type="fig"}). Silencing JARID1B in SK-Hep1 cells inhibited metastatic behavior, both in terms of the number of mice with distant metastasis (Figure [6G](#F6){ref-type="fig"}) and the number of metastatic tumors in the lung of each mouse (Figure [6I](#F6){ref-type="fig"}). Therefore, the *in vivo* results further demonstrate the critical role of JARID1B in HCC metastasis.

JARID1B regulates PTEN expression through H3K4 trimethylation {#s2_6}
-------------------------------------------------------------

To better understand the mechanisms by which JARID1B engaged in HCC development and progression, we performed gene expression profiling on HepG2-pBabe-JARID1B and its control cells. Microarray analyses identified a list of genes significantly differentially expressed after JARID1B overexpression including downregulation of *PTEN* (Figure [7A](#F7){ref-type="fig"}). Furthermore, gene set enrichment analysis indicated that proliferation, neoplasm metastasis and invasion, cell movement and motility, and PTEN related gene signatures were significantly changed in JARID1B overexpression cells (Figure [7B](#F7){ref-type="fig"}), supporting the idea that JARID1B regulates proliferation, EMT and cancer invasion and metastasis. These data also led us to hypothesize that JARID1B exerts these functions possibly via PTEN. To test this, we first determined whether PTEN is a downstream target of JARID1B in HCC cells. Expression of PTEN in the cells with altered JARID1B expression was further evaluated by qRT-PCR and Western blotting. Huh7-pBabe-JARID1B and HepG2-pBabe-JARID1B cells exhibited greatly increased both PTEN mRNA and protein levels ([Supplemental Figure 4A](#SD1){ref-type="supplementary-material"}, Figure [7C](#F7){ref-type="fig"}), whereas silencing JARID1B in SNU423 and SK-Hep1 cells dramatically decreased its mRNA and protein levels ([Supplemental Figure 4B](#SD1){ref-type="supplementary-material"}, Figure [7D](#F7){ref-type="fig"}). Suggesting the regulation of PTEN expression by JARID1B is at transcriptional level. It has been shown that PTEN can regulate PI3K/Akt pathway in many tumor cells \[[@R24], [@R25]\]. So we next examined the role of JARID1B-mediated inhibition of PTEN in the PI3K/Akt pathway. Of note, ectopic JARID1B expression in Huh7 and HepG2 cells remarkably increased the level of phosphorylated PI3K and AKT (Figure [7C](#F7){ref-type="fig"}), whereas silencing JARID1B in SNU423 and SK-Hep1 cells robustly suppressed phosphorylation of PI3K and AKT (Figure [7D](#F7){ref-type="fig"}). While both ectopic expression and silencing of JARID1B not altered the expression of PI3K and AKT mRNA levels ([Supplemental Figure 4A and 4B](#SD1){ref-type="supplementary-material"}).

![JARID1B downregulates PTEN expression in HCC cells\
**A**, supervised hierarchical clustering of the genes differentially expressed after JARID1B overexpression in HepG2 cells. **B**, gene set enrichment analysis was carried out using ConceptGen. **C** and **D**, protein levels of PTEN, PI3K, p-PI3K, AKT, and p-AKT were measured in HCC cells with JARID1B overexpression (C) or silencing (D) by Western blot assay. **E**, the abundance of H3 lysine methylation was assessed in HCC cells with JARID1B overexpression by Western blotting using whole-cell lysate; total H3 and β-actin were used as a loading control. **F**, schematic presentation of three regions relative to the PTEN transcriptional start site used as primers to test histone occupied abundance. **G** and **H**, qChIP was performed to assess H3K4me3 occupancy in HepG2-pBabe-JARID1B (G), SK-Hep1-pSuper-shJARID1B (H) or their control cells. IgG was used as negative control (G and H, left). "Percentage of input" indicates the ratio of DNA fragment of each promoter region bound by H3K4me3 to the total amount of input DNA fragment without H3K4me3 antibody pull-down. \*\*, *P* \< 0.01 is based on the Student *t* test. All results are from three independent experiments. Error bars, SD.](oncotarget-06-12723-g007){#F7}

We then explored how JARID1B regulates PTEN expression at the transcriptional level. JARID1B complexes are frequently involved in chromatin regulation \[[@R26], [@R27]\]. To determine whether JARID1B regulates specific histone modifications in HCC cells, histone modification patterns were measured after modulation of JARID1B expression. Among histone H3K4 and H3K27, we found that only H3K4 was affected by JARID1B. Ectopic expression of JARID1B decreased H3K4me1, H3K4me2, and H3K4me3 (Figure [7E](#F7){ref-type="fig"}) while silencing of JARID1B increased these modification ([Supplemental Figure 4C](#SD1){ref-type="supplementary-material"}). Because H3K4me3 is associated with active transcription, we tested whether JARID1B expression was correlated with the H3K4me3 modification at the *PTEN* gene promoter in HCC cells. Quantitative chromatin immunoprecipitation (qChIP) assays were performed in HepG2-pBabe-JARID1B, SK-Hep1-pSuper-shJARID1B and their corresponding control cells. We found that JARID1B expression was associated with decreased H3K4me3 levels at region -1423 to -1176bp (Figure [7F1](#F7){ref-type="fig"}) and -741 to -513bp (Figure [7F2](#F7){ref-type="fig"}) of the *PTEN* promoter in HepG2-pBabe-JARID1B cells (Figure [7G](#F7){ref-type="fig"}). More occupancy of those *PTEN* gene promoter regions by H3K4me3 was detected in SK-Hep1-pSuper-shJARID1B cells (Figure [7H](#F7){ref-type="fig"}). These results clearly indicate that JARID1B induces transcriptional inactivation of PTEN through regulating H3K4me3 and decreasing H3K4me3 to the *PTEN* gene promoter.

PTEN is a mediator for JARID1B-induced EMT, migration, invasion, and tumor metastasis in HCC cells {#s2_7}
--------------------------------------------------------------------------------------------------

On the basis of the indispensable role of PTEN in the biologic functions of JARID1B, we overexpressed PTEN in HepG2-pBabe-JARID1B cells (Figure [8A](#F8){ref-type="fig"}) and silenced PTEN in SK-Hep1-pSuper-shJARID1B cells (Figure [8E](#F8){ref-type="fig"}). Of note, PTEN overexpression significantly decreased phosphorylation of P13K and Akt in HepG2-pBabe-JARID1B cells (Figure [8B](#F8){ref-type="fig"}). Moreover PTEN overexpression significantly decreased the proliferation (Figure [8C](#F8){ref-type="fig"}) as well as migration, invasion of HepG2-pBabe-JARID1B cells (Figure [8D](#F8){ref-type="fig"}), and EMT markers changes ([Supplemental Figure 6C](#SD1){ref-type="supplementary-material"}). Meanwhile silencing PTEN increased phosphorylation of P13K and AKT in SK-Hep1-pSuper-shJARID1B cells (Figure [8F](#F8){ref-type="fig"}). Moreover silencing PTEN in SK-Hep1-pSuper-shJARID1B cells significantly increased the proliferation (Figure [8G](#F8){ref-type="fig"}) as well as migration, invasion (Figure [8H](#F8){ref-type="fig"}), and EMT markers changes ([Supplemental Figure 6D](#SD1){ref-type="supplementary-material"}). Taken together, these results show that PTEN mediates JARID1B-induced EMT, migration and invasion in hepatocellular carcinoma cells.

![JARID1B regulates PTEN transcriptional expression through H3K4 trimethylation\
**A** and **B**, the abundance of H3 lysine methylation was assessed in HCC cells with JARID1B overexpression (A) or silencing (B) by Western blotting using whole-cell lysate; total H3 and β-actin were used as a loading control. **C**, schematic presentation of three regions relative to the PTEN transcriptional start site used as primers to test histone occupied abundance. **D** and **E**, qChIP was performed to assess H3K4me3 occupancy in HepG2-pBabe-JARID1B (D), SK-Hep1-pSuper-shJARID1B (E) or their control cells. IgG was used as negative control (D and E, left). "Percentage of input" indicates the ratio of DNA fragment of each promoter region bound by H3K4me3 to the total amount of input DNA fragment without H3K4me3 antibody pull-down. \*\*, *P* \< 0.01 is based on the Student *t* test. All results are from three independent experiments. Error bars, SD.](oncotarget-06-12723-g008){#F8}

We next tested the effect of specific blockage of AKT and PI3K pathways on the proliferative and migrative functions of JARID1B. As shown in [Supplemental Figure 5A](#SD1){ref-type="supplementary-material"} and [Supplemental Figure 5D](#SD1){ref-type="supplementary-material"}, treatment with a specific PI3K inhibitor, LY294002, or an AKT inhibitor drastically retarded the level of phosphorylated PI3K and AKT of JARID1B-overexpressing HepG2 cells, and considerably weakened the abilities of these JARID1B-transduced cells to induce proliferation, migration, invasion and EMT markers changes ([Supplemental Figure 5B and 5C](#SD1){ref-type="supplementary-material"}, [Supplemental Figure 5E and 5F](#SD1){ref-type="supplementary-material"}, [Supplemental Figure 6A and 6B](#SD1){ref-type="supplementary-material"}). These data suggested that JARID1B promoted the proliferative and EMT of HCC cells by simultaneously activating both PI3K and AKT pathways.

DISCUSSION {#s3}
==========

Hepatocellular carcinoma (HCC) belongs to common and aggressive human malignancies and is one of the leading causes of death by tumor worldwide \[[@R1]\]. The high mortality rate of HCC is caused by frequent tumor metastasis, postsurgical recurrence, and late detection at advanced stages \[[@R1]\]. However, good diagnostic markers, drug targets and therapeutic strategies are still insufficient for successful treatment of HCC \[[@R1]\]. Histone methylation is a dynamic process that participates in a diverse array of cellular processes and has been found to associate with cancer, including HCC \[[@R28], [@R29]\]. Recently, several histone demethylases have been identified that catalyze the removal of methylation from histone H3 lysine residues \[[@R30], [@R31]\]. Previous studies had found that JARID1B, also named Plu-1, as a histone demethylase that can catalyze the removal of all three methyl groups from the H3K4 lysine residue \[[@R4]\]. However, its role and underlying mechanisms in HCCs still unknown.

To our knowledge, this is the first research to show that JARID1B plays an important part in HCC. We found that as compared with normal tissues, HCC specimens showed overexpression of JARID1B and its overexpression was significantly correlated with distant metastasis in HCC tissues. High expression of JARID1B was associated with decreased overall survival of HCC patients. JARID1B overexpression in HCC cells induced proliferation, EMT, migration, invasion *in vitro* and enhanced tumorigenic and metastatic capacities *in vivo*. In contrast, silencing JARID1B reversed these events in invasive HCC cells. We also showed that a mechanistic link between JARID1B and PTEN through JARID1B-mediated regulation of H3K4m3, which subsequently leads to transcriptional downregulation of PTEN expression. Overexpression of PTEN attenuated JARID1B function and had effects similar to those elicited by direct silencing of JARID1B. These results lead us to propose a model for JARID1B regulation of EMT and metastasis through transcriptional regulation of PTEN in HCCs.

The putative role of JARID1B as an oncogene in cancer development is supported by the observations that JARID1B is highly expressed in prostate cancer and other malignant tumors relative to normal tissues \[[@R12], [@R23], [@R32], [@R13]\]. The fact that JARID1B as a demethylase capable of removing three methyl groups from histone H3 lysine 4, subsequently downregulation several well-known tumor suppressor genes \[[@R27], [@R33], [@R34]\]. Perhaps most convincing is functional evidence showing that the JARID1B demethylase contributes to tumor cell proliferation through the epigenetic repression of a tumor suppressor let-7e in breast cancer cells \[[@R8]\]. Consistent with this research, in the present study we showed that overexpression of JARID1B promoted HCC cells proliferation and enhanced tumor formation in vivo. Interestingly, our study points to a novel function of JARID1B in HCC metastasis through regulating EMT.

HCC cells with ectopic expression of JARID1B displayed an EMT phenotype, including the associated stimulatory effects on migration and invasion *in vitro*. Interestingly, our results indicate that JARID1B not only promotes EMT, but silencing of JARID1B also leads to MET. All of these characteristics induced by JARID1B *in vitro* culminated to increased numbers of distant metastases *in vivo*. These empirical findings provide a mechanistic framework to explain the clinical observations that HCC patients with high levels of JARID1B in tissue samples have more chance of distant metastasis, a significantly shorter overall and disease-free survival.

The roles of several transcription factors as EMT regulators have been extensively reported \[[@R16], [@R35]\]. In our effort to elucidate the mechanism how JARID1B modulates EMT in HCC cells, we identified PTEN as an effective mediator of JARID1B-induced these phenomena. PTEN is one of the most frequently mutated tumor suppressors in human cancer including HCCs \[[@R36], [@R24]\]. PTEN also suppresses migration, genetic deletion of the PTEN tumor suppressor gene promotes cell motility, and PTEN reconstitution or overexpression inhibits cell motility in a variety of cell types. Mechanistically, PTEN reduces cell motility through a variety of pathways, and PI3K/AKT is one important target of PTEN \[[@R37], [@R38]\]. The mechanistic connection between JARID1B and PTEN was previously unknown. In this study, we showed that modulation of JARID1B expression altered the methylation status of H3K4 at the *PTEN* gene promoter, which in turn transcriptionally controlled expression of PTEN. However, we did not detect any influence of JARID1B expression on the methylation status of H3K27. Thus, we conclude that JARID1B transcriptionally inactivates PTEN expression through H3K4 demethylation and reduces H3K4me3 to the *PTEN* gene promoter, and consequently inhibit phosphorylated PI3K and AKT, resulting in increase in proliferation, migration and invasion both *in vitro* and *in vivo*.

EMT is essential for tumor cells to disseminate from adjacent tissues and seed new tumors in distant sites \[[@R15]\]. Our results demonstrated that JARID1B regulated EMT in addition to proliferation, and JARID1B-induced processes are reversible with the suppression of JARID1B expression, providing an optimal therapeutic option to manipulate JARID1B levels in HCC patients' clinical practice.

MATERIALS AND METHODS {#s4}
=====================

Chemicals and antibodies {#s4_1}
------------------------

Lipofectamine 2000 transfection and TRIZOL LS Reagents were purchased from Invitrogen (Grand Island, NY, USA). Antibodies against JARID1B, Histone H3, H3K4me1 (monomethylated K4), H3K4me2 (dimethylated K4), H3K4me3 (trimethylated K4), H3K27me3 (trimethylated K27) were purchased from Abcam (Cambridge, MA, USA). E-cadherin, N-cadherin, vimentin, PTEN, cyclin D1 and β-actin antibodies were from Cell Signaling technology (Danvers, MA, USA). Anti-α-catenin antibody was from BD (Franklin Lakes, NJ, USA). Unless otherwise noted, all other chemicals were from Sigma (St. Louis, MO, USA).

Patients and specimens {#s4_2}
----------------------

Thirty-eight tumor and para-cancerous tissues which, were used for qRT-PCR and Western blot analysis, were randomly collected from HCC patients who underwent curative resection with informed consent between 2011 and 2013 at the Department of Hepatobiliary Surgery, Guilin Medical University, Affiliated Hospital, Guilin, China. All tissues were collected immediately upon resection of the tumors in the operation theater, transported in liquid nitrogen, and then stored at −80°C. Another 178 hepatocellular carcinoma tissues which, were used for immunohistochemical analysis, were randomly collected from HCC patients who underwent curative resection with informed consent between 2006 and 2009 at the Department of Hepatobiliary Surgery, Guilin Medical University, Affiliated Hospital, Guilin, China and Department of General Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. Tumor staging was based on the 6th edition of the tumor-node-metastasis (TNM) classification of the International Union Against Cancer. The clinicopathologic characteristics of the 178 hepatocellular carcinoma tissues are summarized in Table [1](#T1){ref-type="table"}. Follow-up data were summarized at the end of October 2014, with a median observation time of 65.3 months. Study protocols were approved by the Hospital Ethics Committee of Guilin Medical University, and written informed consent was obtained from patients based on the Declaration of Helsinki.

Histological and immunohistochemical analysis {#s4_3}
---------------------------------------------

The normal human liver tissues, human tumor tissues, and lungs dissected from mice were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) overnight and subsequently embedded in paraffin wax. Sections cut at a thickness of 4 μm were stained with hematoxylin and eosin for histological analysis. Immunohistochemical analysis was performed for different markers in these arrays as described previously \[[@R18]\]. The proportion of stained cells (lower, \<30% staining; higher, ≥30% staining) was semiquantitatively determined following published protocols \[[@R19]\].

Cell culture {#s4_4}
------------

HCC cells (ATCC, Manassas, VA, USA) were cultured under the following conditions: SNU-423, SNU-449, and SNU-886 cell lines were cultured using 10% fetal bovine serum (Cat\#10099-141, Invitrogen, Carlsbad, CA) in either RPMI-1640 (Cat\#C11875, Invitrogen). Huh7, HepG2, and SK-Hep-1 cell lines were cultured using 10% fetal bovine serum (Invitrogen) in Dulbecco\'s modified Eagle medium (Cat\#C11965, Invitrogen). Cell culture was according to manufacturer\'s protocol. All the cell lines were grown at 37°C in a 5% CO~2~/95% air atmosphere and were revived every 3 to 4 months.

Establishment of JARID1B and PTEN stable expression and JARID1B and PTEN knockdown cell lines {#s4_5}
---------------------------------------------------------------------------------------------

Retroviral construct containing human pBabe-*JARID1B* cDNA, pcDNA3.1-*PTEN* cDNA and pSuper.retro.puro with shRNA against human *JARID1B* and si*PTEN* were prepared as described previously \[[@R20]\]. The generation of retrovirus supernatants and transfection of hepatocellular carcinoma cells were conducted as described previously \[[@R20]\]. The expression of JARID1B and PTEN was confirmed by qRT-PCR and Western blotting analysis.

Cell proliferation assay {#s4_6}
------------------------

Cells were seeded in 96-well plates in triplicate at densities of 1×10^3^ per well. Cell proliferation was monitored at desired time points using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT). In brief, the MTT assay was performed by adding 20 μl MTT (5mg/ml) for 4 h. Light absorbance of the solution was measured at 570 nm on a microplate reader.

Colony formation assay {#s4_7}
----------------------

Cells were seeded in triplicate at 500 cells/6-cm dishes in complete medium. After 3 weeks of growth, the cells were fixed and stained with crystal violet (0.1%, w/v in 20nM 4-morpholinepropanesulfonic acid), and visible colonies were counted according to cell numbers in each colony.

Wound healing assay {#s4_8}
-------------------

Cells were seeded in 6cm culture plates, and the cell monolayers were wounded by scratching with sterile plastic 200μl micropipette tips and photographed using phase-contrast microscopy. The migration distance of each cell was measured after the photographs were converted to Photoshop files.

Cell invasion and motility assay {#s4_9}
--------------------------------

Invasion of cells was measured in Matrigel (BD, Franklin Lakes, NJ, USA) -coated Transwell inserts (6.5mm, Costar, Manassas, VA, USA) containing polycarbonate filters with 8-μm pores as detailed previously \[[@R21]\]. The inserts were coated with 50μl of 1mg/ml Matrigel matrix according to the manufacturer\'s recommendations. 2×10^5^ cells in 200μl of serum-free medium were plated in the upper chamber, whereas 600μl of medium with 10% fatal bovine serum were added to lower well. After 24hrs incubation, cells that migrated to the lower surface of the membrane were fixed and stained. For each membrane, five random fields were counted at ×10 magnification. Motility assays were similar to Matrigel invasion assay except that the Transwell insert was not coated with Matrigel.

Confocal immunofluorescence microscopy {#s4_10}
--------------------------------------

Cell lines were plated on culture slides (Costar, Manassas, VA, USA). After 24hrs, the cells were rinsed with PBS and fixed with 4% paraformaldehyde, and cell membrane was permeabilized using 0.5% Triton X-100. These cells were then blocked for 30min in 10% BSA and then incubated with primary antibodies overnight at 4°C. After three washes in PBS, the slides were incubated for 1 hour in the dark with FITC-conjugated secondary antibodies (Invitrogen, Grand Island, NY, USA). After three further washes, the slides were stained with DAPI for 5 min to visualize the nuclei, and examined using a Carl Zeiss confocal imaging system (LSM 780) (Carl Zeiss, Jena, Germany).

Western blotting {#s4_11}
----------------

Cells were lysed in lysis buffer and total protein contents were determined by the Bradford method. 30μg of lysis were separated by reducing SDS-PAGE and probed with specific antibodies. Blots were washed and probed with respective secondary peroxidase-conjugated antibodies, and the bands visualized by chemoluminescence (Amersham Biosciences).

qRT-PCR {#s4_12}
-------

Total RNA was extracted using Trizol reagent and cDNA was synthesized using SuperScript II Reverse Transcriptase (Invitrogen). qRT-PCR and data collection were performed with an ABI PRISM 7900HT sequence detection system. The primers used for the amplification of the indicated genes are available upon request.

Gene expression profiling {#s4_13}
-------------------------

Total RNA quality and quantity were determined using Agilent 2100 Bioanalyzer and NanoDrop ND-1000. Affymetrix HU U133 plus 2.0 arrays were used according to manufacturer\'s protocol. The data were initially normalized by robust multiarray average (RMA) normalization algorithms in expression console software (Affymetrix). Significantly altered genes between JARID1B overexpression and its control cells were considered by scatter plots and the genes up- and down-regulated ≥5-fold. Clustering analysis was done using gene list by Gene Cluster v3.0 software, and heat maps were visualized using Java TreeView v1.1.4r3 software. Gene set enrichment analysis was carried out using ConceptGen (<http://conceptgen.ncibi.org/core/conceptGen/index.jsp>). Gene sets were either obtained from the ConceptGen or from published gene signatures.

Chromatin immunoprecipitation (ChIP)-qPCR {#s4_14}
-----------------------------------------

Chromatin Immunoprecipitation kit (Cat. 17-371) was purchased from Millipore and ChIP experiments were carried out essentially as described \[[@R22]\]. Immnuoprecipitated DNA was analyzed on the ABI PRISM 7900HT sequence detection system. The primers used for detection of promoters after ChIP are available upon request.

*In vivo* tumor growth and metastasis {#s4_15}
-------------------------------------

Nude mice were purchased from the Shanghai Slac Laboratory Animal Co. Ltd and maintained in microisolator cages. All animals were used in accordance with institutional guidelines and the current experiments were approved by the Use Committee for Animal Care. For subcutaneous inoculation, different numbers of tumor cells were resuspended in PBS medium with 50% Matrigel and inoculated subcutaneously into the 8-week-old nude mice. The tumors were measured weekly and the tumor volume was calculated according to the formula length × width^2^/2. The mice were killed six weeks after the inoculation. For metastasis assays, cells were resuspended in PBS at a concentration of 1×10^7^ cells ml^−1^. Cell suspension (0.1ml) was injected into tail veins of nude mice. All of the mice were killed by CO~2~ 60 days after inoculation.

Statistical analysis {#s4_16}
--------------------

Results were analyzed with SPSS13.0 statistical software. Correlation between JARID1B expression and clinicopathologic parameters was evaluated using the Chi-square (χ2) test, and quantitative variables were analyzed by the independent t test. The survival probability was estimated by Kaplan-Meier method, and the comparison of survival curves between groups was done with the log-rank test. The statistical significance of the differences between mean values was determined by *P* \<0.05.
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